Bristol Myers Squibb and partner SystImmune announced positive results from two Phase 3 trials for the investigational cancer drug izalontamab brengitecan (iza-bren).
Researchers presented the data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
The drug met dual primary endpoints by improving overall survival and progression-free survival in two difficult-to-treat cancers.
The trials evaluated iza-bren, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC).
Patient groups included those with triple-negative breast cancer and esophageal squamous cell carcinoma.
Iza-bren demonstrated statistically significant and clinically meaningful survival improvements compared to standard chemotherapy in both studies.
The drug maintained a manageable safety profile.
These results position iza-bren as a potential new standard of care for these patient populations.